Sperm Concentration

Fertility marker

Sperm Concentration

Category: Fertility
Unit: /mL

Number of spermatozoa per milliliter of ejaculate. WHO 6th edition lower reference limit is 16,000,000/mL (16 million/mL).

PED Notes

CRITICAL: AAS cause profound suppression of spermatogenesis via HPT axis shutdown. FSH suppression removes the primary signal for Sertoli cells to support sperm development. Most AAS users become severely oligospermic (<5 million/mL) or azoospermic (zero sperm) within 2-3 months of cycle start. HCG maintains intratesticular testosterone but does not fully preserve spermatogenesis without FSH. Recovery post-PCT is highly variable: 6-12 months typical, but some users experience prolonged or incomplete recovery. Values near zero on cycle are expected and not alarming if temporary.

On-cycle context: Most AAS users become severely oligospermic or azoospermic (zero sperm) within 2-3 months. If you are not planning to conceive, this is expected and not alarming — recovery typically occurs 6-12 months post-cessation with PCT.

See Semen Volume marker for full PCT and fertility recovery protocol.

Key points for concentration recovery:

  • HMG -- 75-150 IU 3x/week is the most effective pharmacological intervention for restoring sperm concentration (provides direct FSH stimulation)
  • Enclomiphene -- 12.5-25mg/day to restore endogenous FSH/LH
  • HCG -- 250-500 IU EOD on cycle to maintain baseline spermatogenesis; 1000-1500 IU EOD for 2-3 weeks pre-PCT
  • Recovery timeline: concentration typically returns before motility and morphology normalise
  • If azoospermic after 12+ months of recovery with HMG/SERM, refer to reproductive endocrinologist
  • Baseline semen analysis before first AAS cycle is strongly recommended for future reference

References:

  • McBride, J. A., & Coward, R. M. (2016). Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology, 18(3), 373-380. DOI: 10.4103/1008-682X.173938
  • Lee, J. A., & Ramasamy, R. (2018). Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Translational Andrology and Urology, 7(Suppl 3), S348-S352. DOI: 10.21037/tau.2018.04.11
  • Huijben, M., Lock, M. T. W. T., de Kemp, V. F., de Kort, L. M. O., & van Breda, H. M. K. (2022). Clomiphene citrate for men with hypogonadism: A systematic review and meta-analysis. Andrology, 10(3), 451-469. DOI: 10.1111/andr.13146

History Chart

Reading History

Frequently Asked Questions

Reference Ranges

Standard Range

≥ 16,000,000 /mL

VitalMetrics Range

≥ 20,000,000 /mL

Statistics